Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

Reflecting On Financial Exchanges & Data Stocks’ Q1 Earnings: Nasdaq (NASDAQ:NDAQ)

View original at finance.yahoo.com
Reflecting On Financial Exchanges & Data Stocks’ Q1 Earnings: Nasdaq (NASDAQ:NDAQ) The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Morningstar reported revenues of $644.8 million for Q1 2026, up 10.8% year on year, outperforming analyst expectations by 2.9%, with strong beats on EBITDA and EPS estimates

    60% confidence

  • Nasdaq delivered exceptional first quarter performance with double-digit growth across all three divisions and particular strength in Financial Technology, with mission-critical solutions and execution excellence driving operating leverage and strong earnings growth

    60% confidence

  • Nasdaq reported revenues of $1.41 billion for Q1 2026, up 13.7% year on year, exceeding analyst expectations by 2.2% with an impressive beat on EBITDA and revenue estimates

    60% confidence

Data points we hold from this source

NASDAQ · stock price91.14 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Reflecting On Financial Exchanges & Data Stocks’ Q1 Earnings: Nasdaq (NASDAQ:NDAQ) — Source | Via News | ViaNews EU